Momelotinib Bests Danazol in Symptomatic, Anemic Myelofibrosis
Momelotinib Bests Danazol in Symptomatic, Anemic Myelofibrosis
Momelotinib proved superior to danazol for key outcomes in a phase 3 trial of patients with symptomatic and anemic myelofibrosis.
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->